Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu

Rhea-AI Summary

Agilent Technologies (NYSE: A) has partnered with Hamamatsu Photonics to enhance its end-to-end digital pathology solution. This collaboration integrates Hamamatsu's NanoZoomer S360MD Slide scanner, which converts glass slides into high-resolution digital data, aiming to improve workflow efficiency in pathology laboratories. As pathologists face increased patient loads and remote work challenges, this advanced digital pathology platform intends to facilitate faster diagnostics and better patient outcomes. The partnership reflects Agilent's commitment to advancing precision medicine and supports the growing trend of digital pathology adoption.

Positive

• Integration of Hamamatsu's NanoZoomer S360MD Slide scanner enhances Agilent's digital pathology offering.
• The collaboration aims to improve workflow efficiency, crucial for labs facing increased patient and test loads.
• Supports the growing trend toward digital pathology, positioning Agilent for future growth in precision medicine.

Negative

• None.

An end-to-end digital pathology solution now available

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range including the S360MD Slide scanner system into the Agilent end-to-end digital pathology solution. With the addition of the NanoZoomer Slide scanner systems, which converts glass slides into high-resolution digital data by high-speed scanning, Agilent completes its offering of an open and agnostic digital pathology workflow designed to accelerate breakthroughs in precision medicine.

Today's pathology labs face increasing pressure to manage greater patient and test loads with fewer pathologists, compounded by the growing trend toward remote work situations. To meet this challenge, many pathology laboratories are seeking new ways to improve workflow efficiency and facilitate remote analysis. These circumstances have highlighted the need for a digital pathology solution to increase laboratory efficiency, clinical utility, and test quality.

By incorporating Hamamatsu’s slide scanning capability into its digital pathology solution, Agilent takes a significant step forward in its quest to support pathologists with an advanced platform that can reduce time-to-diagnostic and help improve patient outcomes. This scalable digital pathology workflow features scanners, an image management system, and digital pathology applications that are compatible with Agilent pathology solutions as well as other technology and laboratory information systems (LIS), allowing forward-thinking labs to benefit from flexible, future-proof technology that positions them for growth as requirements evolve.

“Increasing cancer cases and tests have driven pathology labs towards the implementation of digital pathology,” said Lou Welebob, vice president and general manager of Agilent’s Pathology division, Diagnostics and Genomics Group. “This distribution agreement strengthens Agilent’s open and agnostic end-to-end digital pathology offering and demonstrates our commitment to providing superior digital pathology solutions for our customers.”

“Time is critical for patients and clinicians when awaiting a diagnosis. At Hamamatsu, our NanoZoomer Slide scanner digital pathology product line will help revolutionize the diagnostic process, enabling fast turnaround times, more efficient workflows, and more collaboration among pathologists worldwide. We are committed to facilitating the adoption of this transformative technology to help pathologists improve patient care and patient outcomes for every patient and, ultimately, anywhere in the world,” said Laura Pagano, vice president of Sales at Hamamatsu Corporation.

Hamamatsu Photonics K.K. is a leading provider of whole slide imaging systems and related technology such as optical sensors, light sources, and complex instrument systems that use them. The FDA has recently granted 510(k) clearance to market their NanoZoomer S360MD slide scanner system for primary diagnostic use in the US market.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230310005049/en/

Naomi Goumillout

Agilent Technologies

+1.781.266.2819

naomi.goumillout@agilent.com

Source: Agilent Technologies Inc.

FAQ

What is Agilent Technologies' recent partnership about?

Agilent Technologies has partnered with Hamamatsu Photonics to enhance its digital pathology solutions by integrating the NanoZoomer S360MD Slide scanner.

How will Agilent's digital pathology solution benefit pathologists?

The integrated system aims to improve workflow efficiency, reduce time-to-diagnosis, and ultimately enhance patient outcomes.

What challenges are pathology labs facing that Agilent's solution addresses?

Pathology labs are dealing with increased patient and test loads while adapting to remote work environments, necessitating improved efficiency.

What is the significance of the NanoZoomer S360MD Slide scanner?

It converts glass slides into high-resolution digital data, facilitating faster diagnostics and enhancing collaboration among pathologists.

What market trend does this partnership reflect?

The partnership reflects the growing trend toward digital pathology adoption as labs seek solutions to improve efficiency and diagnostic speed.